Cargando…

Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification

The nematode Caenorhabditis elegans (C. elegans) offers a unique opportunity for biological and basic medical researches due to its genetic tractability and well-defined developmental lineage. It also provides an exceptional model for genetic, molecular, and cellular analysis of human disease-relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobet, Robert A., Pan, Xiaoping, Zhang, Baohong, Pak, Stephen C., Asch, Adam S., Lee, Myon-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201220/
https://www.ncbi.nlm.nih.gov/pubmed/25414766
http://dx.doi.org/10.4062/biomolther.2014.084
_version_ 1782340152508547072
author Kobet, Robert A.
Pan, Xiaoping
Zhang, Baohong
Pak, Stephen C.
Asch, Adam S.
Lee, Myon-Hee
author_facet Kobet, Robert A.
Pan, Xiaoping
Zhang, Baohong
Pak, Stephen C.
Asch, Adam S.
Lee, Myon-Hee
author_sort Kobet, Robert A.
collection PubMed
description The nematode Caenorhabditis elegans (C. elegans) offers a unique opportunity for biological and basic medical researches due to its genetic tractability and well-defined developmental lineage. It also provides an exceptional model for genetic, molecular, and cellular analysis of human disease-related genes. Recently, C. elegans has been used as an ideal model for the identification and functional analysis of drugs (or small-molecules) in vivo. In this review, we describe conserved oncogenic signaling pathways (Wnt, Notch, and Ras) and their potential roles in the development of cancer stem cells. During C. elegans germline development, these signaling pathways regulate multiple cellular processes such as germline stem cell niche specification, germline stem cell maintenance, and germ cell fate specification. Therefore, the aberrant regulations of these signaling pathways can cause either loss of germline stem cells or overproliferation of a specific cell type, resulting in sterility. This sterility phenotype allows us to identify drugs that can modulate the oncogenic signaling pathways directly or indirectly through a high-throughput screening. Current in vivo or in vitro screening methods are largely focused on the specific core signaling components. However, this phenotype-based screening will identify drugs that possibly target upstream or downstream of core signaling pathways as well as exclude toxic effects. Although phenotype-based drug screening is ideal, the identification of drug targets is a major challenge. We here introduce a new technique, called Drug Affinity Responsive Target Stability (DARTS). This innovative method is able to identify the target of the identified drug. Importantly, signaling pathways and their regulators in C. elegans are highly conserved in most vertebrates, including humans. Therefore, C. elegans will provide a great opportunity to identify therapeutic drugs and their targets, as well as to understand mechanisms underlying the formation of cancer.
format Online
Article
Text
id pubmed-4201220
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Society of Applied Pharmacology
record_format MEDLINE/PubMed
spelling pubmed-42012202014-11-20 Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification Kobet, Robert A. Pan, Xiaoping Zhang, Baohong Pak, Stephen C. Asch, Adam S. Lee, Myon-Hee Biomol Ther (Seoul) Invited Review The nematode Caenorhabditis elegans (C. elegans) offers a unique opportunity for biological and basic medical researches due to its genetic tractability and well-defined developmental lineage. It also provides an exceptional model for genetic, molecular, and cellular analysis of human disease-related genes. Recently, C. elegans has been used as an ideal model for the identification and functional analysis of drugs (or small-molecules) in vivo. In this review, we describe conserved oncogenic signaling pathways (Wnt, Notch, and Ras) and their potential roles in the development of cancer stem cells. During C. elegans germline development, these signaling pathways regulate multiple cellular processes such as germline stem cell niche specification, germline stem cell maintenance, and germ cell fate specification. Therefore, the aberrant regulations of these signaling pathways can cause either loss of germline stem cells or overproliferation of a specific cell type, resulting in sterility. This sterility phenotype allows us to identify drugs that can modulate the oncogenic signaling pathways directly or indirectly through a high-throughput screening. Current in vivo or in vitro screening methods are largely focused on the specific core signaling components. However, this phenotype-based screening will identify drugs that possibly target upstream or downstream of core signaling pathways as well as exclude toxic effects. Although phenotype-based drug screening is ideal, the identification of drug targets is a major challenge. We here introduce a new technique, called Drug Affinity Responsive Target Stability (DARTS). This innovative method is able to identify the target of the identified drug. Importantly, signaling pathways and their regulators in C. elegans are highly conserved in most vertebrates, including humans. Therefore, C. elegans will provide a great opportunity to identify therapeutic drugs and their targets, as well as to understand mechanisms underlying the formation of cancer. The Korean Society of Applied Pharmacology 2014-09-30 2014-09 /pmc/articles/PMC4201220/ /pubmed/25414766 http://dx.doi.org/10.4062/biomolther.2014.084 Text en Copyright ©2014, The Korean Society of Applied Pharmacology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Invited Review
Kobet, Robert A.
Pan, Xiaoping
Zhang, Baohong
Pak, Stephen C.
Asch, Adam S.
Lee, Myon-Hee
Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
title Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
title_full Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
title_fullStr Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
title_full_unstemmed Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
title_short Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
title_sort caenorhabditis elegans: a model system for anti-cancer drug discovery and therapeutic target identification
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201220/
https://www.ncbi.nlm.nih.gov/pubmed/25414766
http://dx.doi.org/10.4062/biomolther.2014.084
work_keys_str_mv AT kobetroberta caenorhabditiselegansamodelsystemforanticancerdrugdiscoveryandtherapeutictargetidentification
AT panxiaoping caenorhabditiselegansamodelsystemforanticancerdrugdiscoveryandtherapeutictargetidentification
AT zhangbaohong caenorhabditiselegansamodelsystemforanticancerdrugdiscoveryandtherapeutictargetidentification
AT pakstephenc caenorhabditiselegansamodelsystemforanticancerdrugdiscoveryandtherapeutictargetidentification
AT aschadams caenorhabditiselegansamodelsystemforanticancerdrugdiscoveryandtherapeutictargetidentification
AT leemyonhee caenorhabditiselegansamodelsystemforanticancerdrugdiscoveryandtherapeutictargetidentification